CCTx-001

N/A

Report date: 2025/01/02 16:11:31

Base Information

Drug NameCCTx-001

Drug Alias NameCCTx-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-1 receptor accessory protein inhibitors

TargetsInterleukin-1 receptor accessory protein

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenGermanyFrance +[4]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAdvesya SAS

China Registration ClassN/A

Develop Information

Active CompaniesAdvesya SAS

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A